Peripheral neuropathy risk factors
|
Peripheral neuropathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Peripheral neuropathy risk factors On the Web |
|
American Roentgen Ray Society Images of Peripheral neuropathy risk factors |
|
Risk calculators and risk factors for Peripheral neuropathy risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]
Overview
Risk Factors
The most potent risk factor in the development of peripheral neuropathy is diabetes mellitus . Other common risk factors in the development of peripheral neuropathy include [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
Common Risk Factors
- Common risk factors in the development of peripheral neuropathy may be occupational, environmental, genetic, and viral.[1][2][1][3][4][5]
- Common risk factors in the development of peripheral neuropathy include:[1][2][1][3][6][7][8][3][4][9][10][11][5][12][13][14]
- Alcohol abuse
- Vitamin deficiencies:
- Stress
- Infections such as:
- kidney disease
- Liver disease
- Genetic diseases
- Amyloidosis
- Cancer
- Dyslipidemia
- Family history of neuropathy
- Repetitive motion
- Thyroid disorders
- Immune system disorders such as:
- Drugs
References
- ↑ 1.0 1.1 1.2 1.3 Khawaja N, Abu-Shennar J, Saleh M, Dahbour SS, Khader YS, Ajlouni KM (2018). "The prevalence and risk factors of peripheral neuropathy among patients with type 2 diabetes mellitus; the case of Jordan". Diabetol Metab Syndr. 10: 8. doi:10.1186/s13098-018-0309-6. PMC 5822644. PMID 29483946.
- ↑ 2.0 2.1 Mørkrid K, Ali L, Hussain A (2010). "Risk factors and prevalence of diabetic peripheral neuropathy: A study of type 2 diabetic outpatients in Bangladesh". Int J Diabetes Dev Ctries. 30 (1): 11–7. doi:10.4103/0973-3930.60004. PMC 2859278. PMID 20431800.
- ↑ 3.0 3.1 3.2 Gogia S, Rao CR (2017). "Prevalence and Risk Factors for Peripheral Neuropathy among Type 2 Diabetes Mellitus Patients at a Tertiary Care Hospital in Coastal Karnataka". Indian J Endocrinol Metab. 21 (5): 665–669. doi:10.4103/ijem.IJEM_43_17. PMC 5628533. PMID 28989871.
- ↑ 4.0 4.1 Hébert HL, Veluchamy A, Torrance N, Smith BH (2017). "Risk factors for neuropathic pain in diabetes mellitus". Pain. 158 (4): 560–568. doi:10.1097/j.pain.0000000000000785. PMC 5359789. PMID 27941499.
- ↑ 5.0 5.1 Giubelan LI, Cupşa A, Dumitrescu F, Niculescu I, Stoian AC (2014). "Considerations About Risk Factors for Peripheral Neuropathies in Romanian HIV-Infected Patients". Curr Health Sci J. 40 (1): 42–6. doi:10.12865/CHSJ.40.01.07. PMC 4006335. PMID 24791204.
- ↑ Hasani N, Khosrawi S, Hashemipour M, Haghighatiyan M, Javdan Z, Taheri MH; et al. (2013). "Prevalence and related risk-factors of peripheral neuropathy in children with insulin-dependent diabetes mellitus". J Res Med Sci. 18 (2): 132–6. PMC 3724374. PMID 23914216.
- ↑ Papanas N, Ziegler D (2015). "Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015". Rev Diabet Stud. 12 (1–2): 48–62. doi:10.1900/RDS.2015.12.48. PMC 5397983. PMID 26676661.
- ↑ Jaiswal M, Divers J, Dabelea D, Isom S, Bell RA, Martin CL; et al. (2017). "Prevalence of and Risk Factors for Diabetic Peripheral Neuropathy in Youth With Type 1 and Type 2 Diabetes: SEARCH for Diabetes in Youth Study". Diabetes Care. 40 (9): 1226–1232. doi:10.2337/dc17-0179. PMC 5566278. PMID 28674076.
- ↑ Yang CP, Lin CC, Li CI, Liu CS, Lin WY, Hwang KL; et al. (2015). "Cardiovascular Risk Factors Increase the Risks of Diabetic Peripheral Neuropathy in Patients With Type 2 Diabetes Mellitus: The Taiwan Diabetes Study". Medicine (Baltimore). 94 (42): e1783. doi:10.1097/MD.0000000000001783. PMC 4620799. PMID 26496307.
- ↑ Hanewinckel R, van Oijen M, Ikram MA, van Doorn PA (2016). "The epidemiology and risk factors of chronic polyneuropathy". Eur J Epidemiol. 31 (1): 5–20. doi:10.1007/s10654-015-0094-6. PMC 4756033. PMID 26700499.
- ↑ El-Cheikh J, Stoppa AM, Bouabdallah R, de Lavallade H, Coso D, de Collela JM; et al. (2008). "Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma". Clin Lymphoma Myeloma. 8 (3): 146–52. doi:10.3816/CLM.2008.n.017. PMID 18650177.
- ↑ Wadley AL, Cherry CL, Price P, Kamerman PR (2011). "HIV neuropathy risk factors and symptom characterization in stavudine-exposed South Africans". J Pain Symptom Manage. 41 (4): 700–6. doi:10.1016/j.jpainsymman.2010.07.006. PMID 21145196.
- ↑ Bramuzzo M, Stocco G, Montico M, Arrigo S, Calvi A, Lanteri P; et al. (2017). "Risk Factors and Outcomes of Thalidomide-induced Peripheral Neuropathy in a Pediatric Inflammatory Bowel Disease Cohort". Inflamm Bowel Dis. 23 (10): 1810–1816. doi:10.1097/MIB.0000000000001195. PMID 28817461.
- ↑ Kerckhove N, Collin A, Condé S, Chaleteix C, Pezet D, Balayssac D (2017). "Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review". Front Pharmacol. 8: 86. doi:10.3389/fphar.2017.00086. PMC 5323411. PMID 28286483.